Unlock instant, AI-driven research and patent intelligence for your innovation.

Porcine circovirus inactivated vaccine and porcine cytokine combined immune method

A technology of porcine circovirus and inactivated vaccine, applied in the field of immunization, can solve the problem of uncertain immunization effect, and achieve the effect of shortening the blank period of immunization, reducing morbidity and mortality, and reducing morbidity.

Inactive Publication Date: 2015-12-16
章红兵
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The application of commercialized PCV inactivated vaccine has brought positive significance to the prevention and treatment of PCVD in my country, but the immune effect of porcine circovirus type 2 inactivated vaccine is not sure after being used in large-scale pig farms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Porcine circovirus inactivated vaccine and porcine cytokine combined immune method
  • Porcine circovirus inactivated vaccine and porcine cytokine combined immune method
  • Porcine circovirus inactivated vaccine and porcine cytokine combined immune method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Combined Application of IL-2, 4 and Porcine PCV2 Inactivated Vaccine

[0017] experiment method:

[0018] Sixty healthy piglets with similar genetic background and 14-day-old “Du×Chang×Da” three-way cross were randomly divided into 2 groups, with 3 replicates in each group and 10 pigs in each replicate. Routine feeding and management, free access to food and water. The test group was injected with PCV2 inactivated vaccine 1mL+IL-2, 40.1mL at the age of 14 and 28 days, and the control group was injected with 1mL of PCV2 inactivated vaccine at the age of 14 and 28 days.

[0019] On the 21st, 35th, and 49th day of the test, 4 piglets (half male and half female) were randomly selected in each group to collect 2 parts of blood from the anterior vena cava, and 1 part of 2 mL was injected into a sterile penicillin vial, and heparin sodium was added for anticoagulation. Cell Transformation Assay. 1 mL of blood was collected in a dipotassium ethylenediaminetetraacetic acid (E...

Embodiment 2

[0037] Combined Application of IL-4 and Porcine PCV2 Inactivated Vaccine

[0038] experiment method:

[0039] A total of 120 Du hybrid piglets aged 13-15 days, with similar body weight and the same genetic background were selected and randomly divided into 3 groups, with 4 replicates in each group and 10 pigs in each replicate. Each group was injected with 1 dose of PCV2 inactivated vaccine + porcine interleukin-4 (IL-4) 250,000 IU, 1 dose of PCV2 inactivated vaccine and 1 mL of normal saline on the first day of the test and 14 days after the test.

[0040] After the above-mentioned immunization experiment was over, 633 piglets aged 13-15 days were selected to carry out a large group experiment. The test pigs were randomly divided into two groups. One group was injected with 1 head of PCV2 inactivated vaccine + IL-4.25 million IU, and the other group was injected with 1 head of PCV2 inactivated vaccine without interleukin injection. The immunization was repeated once every 14...

Embodiment 3

[0053] Combined Application Test of Pig Genetic Engineering Interferon and PCV2 Inactivated Vaccine

[0054] experiment method:

[0055] Sixty 14-day-old piglets were randomly divided into four groups, A, B, C, and D, with 15 piglets in each group. Both the treatment group and the control group were intramuscularly injected with 1ml of PCV2 inactivated vaccine per head at the age of 14 days and 28 days, but the treatment group was injected with porcine genetically engineered interferon at the other side of the neck at the same time, and the dose of group A was 500,000 active Units, 250,000 active units in group B, 125,000 active units in group C, and blank control in group D, without injecting porcine genetically engineered interferon.

[0056] Antibody determination by ELISA Blood was collected from the anterior vena cava of each group on 14d, 21d, 28d and 35d after the first immunization for PCV2 antibody detection. The detection of PCV2 antibody in serum samples was perfo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a porcine circovirus inactivated vaccine and porcine cytokine combined immune method. The porcine circovirus inactivated vaccine and porcine cytokine combined immune method is characterized in that porcine circovirus inactivated vaccine and porcine cytokine are simultaneously injected, wherein porcine cytokine is one of IL-4, a composition of IL-2 and IL-4, porcine gene engineering interferon and a porcine transfer factor. According to the porcine circovirus inactivated vaccine and porcine cytokine combined immune method, interleukin 2,4 and PCV2 inactivated vaccine are used together for immunity, so that the piglet cell immunity level can be remarkably improved; IL-4 and PCV2 inactivated vaccine are used in combination to remarkably reduce the sickness rate and the mortality of piglets, improve the average daily weight increment and feed conversion of the piglets and remarkably improve the economic benefits. Recombinant porcine interferon and PCV2 inactivated vaccine are used in combination to improve the survival rate of the piglets, reduce the sickness rate of the piglets and improve the antibody level after PCV2 vaccine immunity; the transfer factor and PCV2 inactivated vaccine are used in combination to shorten the immunity blanking period, improve the immunity effect and reduce the sickness rate.

Description

technical field [0001] The invention relates to an immunization method, in particular to a combined immunization method of porcine circovirus inactivated vaccine and pig cytokines. Background technique [0002] Porcine circovirus disease (PCVD) is an infectious disease of pigs caused by porcine circovirus type 2 (PCV2). Diseases such as nephrotic syndrome (PDNS), neonatal congenital tremor (CT), proliferative necrotizing pneumonia (PNP) and enteritis are also one of the primary pathogens that cause porcine respiratory disease syndrome (PRDC). The positive rate of this disease in our country is increasing year by year. It has the characteristics of wide epidemic range, severe infection of pigs at various growth stages, and prominent mixed infection. It has become the number one killer that restricts the stability and development of the current pig industry, and seriously threatens the development of my country's pig industry. The application of commercialized PCV inactivated...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12A61P31/14A61K38/20A61K38/19
Inventor 章红兵
Owner 章红兵